143 related articles for article (PubMed ID: 9838547)
1. A one-year comparative study of Neoral vs Consupren in de novo renal transplant patients.
Stephan A; Masri MA; Barbari A; Aoun S; Rizk S; Kamel G
Transplant Proc; 1998 Nov; 30(7):3533-4. PubMed ID: 9838547
[No Abstract] [Full Text] [Related]
2. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral.
Cattral MS; Hemming AW; Greig PD; Rowsell C; Chari R; Wright E; Donat D; Cole E; Levy GA
Transplant Proc; 1998 Aug; 30(5):1946. PubMed ID: 9723346
[No Abstract] [Full Text] [Related]
3. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group.
Korn A; Färber L; Maibücher A; Buchholz B; Offermann G
Transplant Proc; 1997 Nov; 29(7):2945-7. PubMed ID: 9365623
[No Abstract] [Full Text] [Related]
4. Neoral vs Sandimmun: interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients. The U. K. Neoral Study Group.
Lodge JP; Pollard SG
Transplant Proc; 1997; 29(1-2):272-3. PubMed ID: 9122991
[No Abstract] [Full Text] [Related]
5. Antibody therapy in steroid-resistant rejection.
Waiser J; Budde K; Schreiber M; Böhler T; Löbermann LA; Neumayer HH
Transplant Proc; 1998 Aug; 30(5):1778-9. PubMed ID: 9723279
[No Abstract] [Full Text] [Related]
6. Safety and effectiveness of microemulsion cyclosporine in renal allograft recipients: 1-year follow-up study.
Park K; Kim MS; Kim SI; Kim YS; Moon JI
Transplant Proc; 1998 Nov; 30(7):3556-7. PubMed ID: 9838557
[No Abstract] [Full Text] [Related]
7. Neoral reduces the incidence of acute rejection after renal transplantation.
Sandrini S; Setti G; Gaggia P; Chiappini R; Maffeis R; Tardanico R; Maiorca R
Transplant Proc; 1998 Aug; 30(5):1758-9. PubMed ID: 9723269
[No Abstract] [Full Text] [Related]
8. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment.
Abendroth D; Buchholz B; Land W; May G; Wiesel M; Färber L; Korn A; Maibücher A
Transplant Proc; 1997; 29(1-2):275-6. PubMed ID: 9122993
[No Abstract] [Full Text] [Related]
9. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
Niese D
Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
[No Abstract] [Full Text] [Related]
10. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors.
Ohshima S; Fujita T; Ono Y; Kinukawa T; Katoh N; Matsuura O
Artif Organs; 1996 Oct; 20(10):1130-6. PubMed ID: 8896734
[TBL] [Abstract][Full Text] [Related]
11. A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients.
Stephan AG; Barbari A; Masri M; Kamel G; Barakat Khoury W; Karam A; Mokhbat J; Kilany H
Transplant Proc; 1998 Nov; 30(7):3563-4. PubMed ID: 9838560
[No Abstract] [Full Text] [Related]
12. Experience with new cyclosporine formulations: Consupren and Neoral in renal transplant patients.
Barbari A; Stephan A; Kamel G; Kilany H; Masri MA
Transplant Proc; 1997 Nov; 29(7):2941-4. PubMed ID: 9365622
[No Abstract] [Full Text] [Related]
13. Increasing incidence of steroid resistant rejection in kidney transplantation.
Arrazola L; Sozen H; Humar A; Papalois V; Uknis M; Matas AJ
Transplant Proc; 2000 Nov; 32(7):1767. PubMed ID: 11119926
[No Abstract] [Full Text] [Related]
14. Use of microemulsion form cyclosporine immediately after kidney transplantation without intravenous cyclosporine.
Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S
Transplant Proc; 1998 Aug; 30(5):1760-1. PubMed ID: 9723270
[No Abstract] [Full Text] [Related]
15. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral.
Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A
Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676
[No Abstract] [Full Text] [Related]
16. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
[No Abstract] [Full Text] [Related]
17. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
18. Early or delayed onset of cyclosporine by sequential immunosuppression?
Wienand P; Schröder T; Baldamus C
Transpl Int; 1992; 5 Suppl 1():S121-2. PubMed ID: 14621753
[TBL] [Abstract][Full Text] [Related]
19. Long-term results and risk factors of quadruple immunosuppression in renal transplantation.
Hiesse C; Kriaa F; Eschwege P; Boubenider S; Marchand S; Benoit G; Charpentier B
Transplant Proc; 1999; 31(1-2):1111-2. PubMed ID: 10083496
[No Abstract] [Full Text] [Related]
20. Long-term effects of single versus double CsA dosing in kidney transplantation.
Tarantino A; Montagnino G; Cesana B; Aroldi A; Campise M; Passerini P; Ponticelli C
Transplant Proc; 2001; 33(7-8):3409-10. PubMed ID: 11750459
[No Abstract] [Full Text] [Related]
[Next] [New Search]
